These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25519174)

  • 1. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.
    Zhang Y; Liu J; Li S; Xu RX; Sun J; Tang Y; Li JJ
    BMC Cardiovasc Disord; 2014 Dec; 14():192. PubMed ID: 25519174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms.
    Xu RX; Liu J; Li XL; Li S; Zhang Y; Jia YJ; Sun J; Li JJ
    J Transl Med; 2015 Mar; 13():87. PubMed ID: 25889684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
    Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
    J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
    Yang X; Zhang J; Chen L; Wu Q; Yu C
    Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors.
    Persson L; Gälman C; Angelin B; Rudling M
    Endocrinology; 2009 Mar; 150(3):1140-6. PubMed ID: 19008317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.
    Shende VR; Wu M; Singh AB; Dong B; Kan CF; Liu J
    J Lipid Res; 2015 Apr; 56(4):801-9. PubMed ID: 25652089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
    Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.
    Dong B; Singh AB; Shende VR; Liu J
    Int J Mol Med; 2017 Mar; 39(3):749-756. PubMed ID: 28204827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
    Yang SH; Xu RX; Cui CJ; Wang Y; Du Y; Chen ZG; Yao YH; Ma CY; Zhu CG; Guo YL; Wu NQ; Sun J; Chen BX; Li JJ
    Cardiovasc Diabetol; 2018 Apr; 17(1):48. PubMed ID: 29618348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.
    Miyazawa H; Tabeta K; Miyauchi S; Aoki-Nonaka Y; Domon H; Honda T; Nakajima T; Yamazaki K
    Lipids Health Dis; 2012 Sep; 11():121. PubMed ID: 22992388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
    Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
    J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.
    Dong B; Wu M; Li H; Kraemer FB; Adeli K; Seidah NG; Park SW; Liu J
    J Lipid Res; 2010 Jun; 51(6):1486-95. PubMed ID: 20048381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells.
    Leblond F; Seidah NG; Précourt LP; Delvin E; Dominguez M; Levy E
    Am J Physiol Gastrointest Liver Physiol; 2009 Apr; 296(4):G805-15. PubMed ID: 19179626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.